Non-B, non-C hepatocellular carcinoma (Review)

Nishikawa,Hiroki; Osaki,Yukio

doi:10.3892/ijo.2013.2061

Non-B, non-C hepatocellular carcinoma (Review)

Authors:
- Hiroki Nishikawa
- Yukio Osaki
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Tennoji-ku, Osaka 543-0027, Japan
Published online on: August 20, 2013 https://doi.org/10.3892/ijo.2013.2061
Pages: 1333-1342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although most hepatocellular carcinoma (HCC) is related to viral infection, there is a substantial population of HCC patients (5-20%) who are negative for both markers of hepatitis B virus and hepatitis C virus infection [non-B, non-C (NBNC) hepatitis] in Japan and the incidence of NBNC-HCC has recently tended to increase. The most common cause of liver disease in developed countries is non‑alcoholic fatty liver disease (NAFLD), which includes non‑alcoholic steatohepatitis (NASH) and its related complications. Increased body mass index and diabetes mellitus are associated with developing NAFLD and NASH, which is a severe form of NAFLD. Furthermore, increasing clinical evidence supports the fact that NAFLD and NASH can progress to liver cirrhosis and even HCC. A detailed understanding of the epidemiology, etiology, molecular mechanism, clinical features and prognosis of NBNC-HCC could improve our screening and therapy of this disease. In this review, we primarily focus on clinical aspects of NBNC-HCC and refer to our current knowledge of this cancer.

View Figures

View References

1.	Livraghi T, Mäkisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg. 100:22–29. 2011.PubMed/NCBI
2.	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
3.	De Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol. 56(Suppl 1): S75–S87. 2012.
4.	Nishikawa H, Osaki Y, Iguchi E, Takeda H, Matsuda F, Nakajima J, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R and Kimura T: Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol. Oct 12–2012.(Epub ahead of print).
5.	Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T and Osaki Y: Surgical resection for hepatocellular carcinoma: clinical outcomes and safety in elderly patients. Eur J Gastroenterol Hepatol. 25:912–919. 2013. View Article : Google Scholar : PubMed/NCBI
6.	Umemura T, Ichijo T, Yoshizawa K, Tanaka E and Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 44(Suppl 19): 102–107. 2009. View Article : Google Scholar
7.	Tokushige K, Hashimoto E, Horie Y, Taniai M and Higuchi S: Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 46:1230–1237. 2011. View Article : Google Scholar
8.	Kaibori M, Ishizaki M, Matsui K and Kwon AH: Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg. 204:300–307. 2012. View Article : Google Scholar
9.	Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M and Aizawa Y: Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol. 43:967–974. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S and Chayama K: Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 42:368–375. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Suzuki Y, Ohtake T, Nishiguchi S, Hashimoto E, Aoyagi Y, Onji M and Kohgo Y: The Japan Non-B, Non-C Liver Cirrhosis Study Group: Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res. Dec 26–2012.(Epub ahead of print).
12.	Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y and Kudo M: Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 84(Suppl 1): 43–49. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L and Salizzoni M: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123:134–140. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM and Lok AS: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 36:1349–1354. 2002. View Article : Google Scholar : PubMed/NCBI
15.	Torres DM and Harrison SA: Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis. 32:30–38. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 348:1625–1638. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Shirai Y, Douhara A and Fukui H: Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress. Curr Med Chem. 19:1889–1898. 2012. View Article : Google Scholar
18.	Yasui K, Hashimoto E, Tokushige K, Koike K, Shima T, Kanbara Y, Saibara T, Uto H, Takami S, Kawanaka M and Komorizono Y: Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res. 42:767–773. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Chung H, Ueda T and Kudo M: Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 53:39–43. 2010.PubMed/NCBI
20.	Schaefer EA and Chung RT: Anti-hepatitis C virus drugs in development. Gastroenterology. 142:1340–1350. 2012. View Article : Google Scholar : PubMed/NCBI
21.	Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F and Schulz J: A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 19(Suppl 2): 1–26. 2012. View Article : Google Scholar : PubMed/NCBI
22.	Rosen HR: Clinical practice. Chronic hepatitis C infection N Engl J Med. 364:2429–2438. 2011.PubMed/NCBI
23.	Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK and Canbay A: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 128:2436–2443. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S and Nardi G: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 155:323–331. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Corrao G, Bagnardi V, Zambon A and La Vecchia C: A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med. 38:613–619. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Sookoian S and Pirola CJ: The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine. Clin Liver Dis. 16:467–485. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ and Chen SY: Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol. 9:1106–1110. 2003.PubMed/NCBI
28.	Ong JP and Younossi ZM: Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 11:1–16. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Kojima S, Watanabe N, Numata M, Ogawa T and Matsuzaki S: Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 38:954–961. 2003.PubMed/NCBI
30.	Harrison SA, Torgerson S and Hayashi PH: The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 98:2042–2047. 2003. View Article : Google Scholar : PubMed/NCBI
31.	Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW and Powell LW: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 11:74–80. 1990.PubMed/NCBI
32.	Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K and Shiratori K: Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 44(Suppl 19): 89–95. 2009. View Article : Google Scholar
33.	Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, Sohara N, Kakizaki S, Mochida Y, Shimura T and Sunose Y: Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 19:827–834. 2007. View Article : Google Scholar : PubMed/NCBI
34.	Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K and Shiratori K: Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol. 39:1215–1218. 2004. View Article : Google Scholar : PubMed/NCBI
35.	Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL and Khettry U: Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol. 33:1098–1104. 2002. View Article : Google Scholar : PubMed/NCBI
36.	Starley BQ, Calcagno CJ and Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 51:1820–1832. 2010. View Article : Google Scholar : PubMed/NCBI
37.	Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF and Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 51:1972–1978. 2010. View Article : Google Scholar : PubMed/NCBI
38.	Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K and Shiratori K: Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 24:248–254. 2009. View Article : Google Scholar : PubMed/NCBI
39.	Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA and McGlynn KA: Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 54:463–471. 2011. View Article : Google Scholar : PubMed/NCBI
40.	El-Serag HB, Tran T and Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 126:460–468. 2004. View Article : Google Scholar : PubMed/NCBI
41.	Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G and Wang L: Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 130:1639–1648. 2012. View Article : Google Scholar : PubMed/NCBI
42.	Neuschwander-Tetri BA and Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 37:1202–1219. 2003. View Article : Google Scholar : PubMed/NCBI
43.	Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA and Maldonado-Garza H: Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 15:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
44.	Allison ME, Wreghitt T, Palmer CR and Alexander GJ: Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 21:1135–1139. 1994. View Article : Google Scholar : PubMed/NCBI
45.	El-Serag HB, Johnson ML, Hachem C and Morgana RO: Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 136:1601–1608. 2009. View Article : Google Scholar : PubMed/NCBI
46.	Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, Abiru S, Nakagawa Y, Shigeno M, Miyazoe S, Ichikawa T, Ishikawa H, Nakao K and Eguchi K: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 97:3036–3043. 2003. View Article : Google Scholar : PubMed/NCBI
47.	Shimizu M, Tanaka T and Moriwaki H: Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol. 35:191–202. 2013. View Article : Google Scholar : PubMed/NCBI
48.	Bianchini F, Kaaks R and Vainio H: Overweight, obesity, and cancer risk. Lancet Oncol. 3:565–574. 2002. View Article : Google Scholar : PubMed/NCBI
49.	Larsson SC and Wolk A: Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 97:1005–1008. 2007.PubMed/NCBI
50.	Moller H, Mellemgaard A, Lindvig K and Olsen JH: Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer. 30A:344–350. 1994. View Article : Google Scholar : PubMed/NCBI
51.	Oh SW, Yoon YS and Shin SA: Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 23:4742–4754. 2005. View Article : Google Scholar
52.	Drakesmith H and Prentice A: Viral infection and iron metabolism. Nat Rev Microbiol. 6:541–552. 2008. View Article : Google Scholar
53.	Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A and Vecchione R: Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steatohepatitis. J Hepatol. 50:351–357. 2009. View Article : Google Scholar : PubMed/NCBI
54.	Ioannou GN, Weiss NS and Kowdley KV: Relationship between transferrin-iron saturation, alcohol consumption, and the incidence of cirrhosis and liver cancer. Clin Gastroenterol Hepatol. 5:624–629. 2007. View Article : Google Scholar : PubMed/NCBI
55.	Harada K, Hirohara J, Ueno Y, Nakano T, Kakuda Y, Tsubouchi H, Ichida T and Nakanuma Y: Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology. 57:1942–1949. 2013. View Article : Google Scholar : PubMed/NCBI
56.	Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, Ohta H, Shimada M, Mita E, Hijioka T, Yamashita H, Takezaki E, Muro T, Sakai H, Nakamuta M, Abiru S, Komori A, Ito M, Yatsuhashi H, Nakamura M and Ishibashi H: Japanese NHO-Liver-network study group: Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int. 32:837–844. 2012. View Article : Google Scholar
57.	Harnois DM, Gores JG, Ludwig J, Steers JL, LaRusso NE and Wiesner RH: Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol. 27:512–516. 1997. View Article : Google Scholar : PubMed/NCBI
58.	Razumilava N, Gores GJ and Lindor KD: Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 54:1842–1852. 2011. View Article : Google Scholar : PubMed/NCBI
59.	Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH and Kushner JP: Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med. 318:1355–1362. 1988. View Article : Google Scholar : PubMed/NCBI
60.	Powell LW, Subramaniam VN and Yapp TR: Haemochromatosis in the new millennium. J Hepatol. 32:48–62. 2000. View Article : Google Scholar
61.	Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S and Fraumeni JF Jr: Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer. 60:160–162. 1995. View Article : Google Scholar : PubMed/NCBI
62.	Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A and Fargion S: Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 33:647–651. 2001. View Article : Google Scholar : PubMed/NCBI
63.	Yang Q, McDonnell SM, Khoury MJ, Cono J and Parrish RG: Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med. 129:946–953. 1998. View Article : Google Scholar : PubMed/NCBI
64.	Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, Lindgren S, Lööf L, Stål P, Wallerstedt S, Almer S, Sandberg-Gertzén H and Askling J: Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 125:1733–1741. 2003. View Article : Google Scholar : PubMed/NCBI
65.	Wang Y, Xie CL, Fu DL, Lu L, Lin Y, Dong QQ, Wang XT and Zheng GQ: Clinical efficacy and safety of Chinese herbal medicine for Wilson's disease: a systematic review of 9 randomized controlled trials. Complement Ther Med. 20:143–154. 2012.
66.	Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y and Onji M: Japan Etiology of Liver Cirrhosis Study Group: Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 45:86–94. 2010. View Article : Google Scholar : PubMed/NCBI
67.	Tanaka M and Wanless IR: Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology. 27:488–496. 1998. View Article : Google Scholar : PubMed/NCBI
68.	Okuda K: Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis. 22:15–26. 2002. View Article : Google Scholar : PubMed/NCBI
69.	Ren W, Qi X, Yang Z, Han G and Fan D: Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol. 25:830–841. 2013. View Article : Google Scholar : PubMed/NCBI
70.	Raimondo G, Pollicino T, Cacciola I and Squadrito G: Occult hepatitis B virus infection. J Hepatol. 46:160–170. 2007. View Article : Google Scholar : PubMed/NCBI
71.	Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR and Zoulim F: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 49:652–657. 2008. View Article : Google Scholar : PubMed/NCBI
72.	Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T and Osaki Y: Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma. Oncol Rep. 30:91–98. 2013.
73.	Raimondo G, Caccamo G, Filomia R and Pollicino T: Occult HBV infection. Semin Immunopathol. 35:39–52. 2013. View Article : Google Scholar
74.	Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzu D and Raimondo G: Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 106:1326–1330. 2006. View Article : Google Scholar : PubMed/NCBI
75.	Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E and Raimondo G: Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 126:102–110. 2004. View Article : Google Scholar : PubMed/NCBI
76.	Wu HC and Santella R: The role of aflatoxins in hepatocellular carcinoma. Hepat Mon. 12:e72382012.PubMed/NCBI
77.	Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, Wang LW and Santella RM: Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology. 24:38–42. 1996. View Article : Google Scholar : PubMed/NCBI
78.	Kawaguchi T, Izumi N, Charlton MR and Sata M: Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 54:1063–1070. 2011. View Article : Google Scholar : PubMed/NCBI
79.	Price JA, Kovach SJ, Johnson T, Koniaris LG, Cahill PA, Sitzmann JV and McKillop IH: Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology. 36:1089–1097. 2002. View Article : Google Scholar : PubMed/NCBI
80.	Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S and Gentilini P: Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol. 88:1744–1748. 1993.
81.	Kasprzak A and Adamek A: The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (Review). Int J Oncol. 41:1919–1931. 2012.PubMed/NCBI
82.	Shimizu M, Kubota M, Tanaka T and Moriwaki H: Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci. 13:579–595. 2012. View Article : Google Scholar : PubMed/NCBI
83.	Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M and Hotamisligil GS: A central role for JNK in obesity and insulin resistance. Nature. 420:333–336. 2002. View Article : Google Scholar : PubMed/NCBI
84.	Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM and Sanyal AJ: Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 134:568–576. 2008. View Article : Google Scholar : PubMed/NCBI
85.	Duan XF, Tang P, Li Q and Yu ZT: Obesity, adipokines and hepatocellular carcinoma. Int J Cancer. Feb 12–2013.(Epub ahead of print).
86.	Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T and Ohnishi S: Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol. 24:1669–1676. 2009. View Article : Google Scholar : PubMed/NCBI
87.	Brakenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T and Cao Y: Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA. 101:2476–2481. 2004. View Article : Google Scholar : PubMed/NCBI
88.	Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T and Asada K: Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology. 44:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
89.	Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T and Sato N: Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 122:1399–1410. 2002. View Article : Google Scholar : PubMed/NCBI
90.	Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
91.	Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA and Diehl AM: Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys. 378:259–268. 2000. View Article : Google Scholar : PubMed/NCBI
92.	Nowsheen S, Aziz K, Kryston TB, Ferguson NF and Georgakilas A: The interplay between inflammation and oxidative stress in carcinogenesis. Curr Mol Med. 12:672–680. 2012. View Article : Google Scholar : PubMed/NCBI
93.	Marnett LJ: Oxyradicals and DNA damage. Carcinogenesis. 21:361–370. 2000. View Article : Google Scholar : PubMed/NCBI
94.	Petta S and Craxì A: Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Des. 16:741–752. 2010. View Article : Google Scholar : PubMed/NCBI
95.	Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, Dohmen T, Kataoka E, Sato W, Goto T and Sasaki J: Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J Hepatol. 50:562–571. 2009. View Article : Google Scholar : PubMed/NCBI
96.	Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P and Poynard T: Liver fibrosis in overweight patients. Gastroenterology. 118:1117–1123. 2000. View Article : Google Scholar : PubMed/NCBI
97.	Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R and Ruggiero G: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 33:1358–1364. 2001. View Article : Google Scholar : PubMed/NCBI
98.	Westin J, Nordlinder H, Lagging M, Norkrans G and Wejstal R: Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 37:837–842. 2002. View Article : Google Scholar : PubMed/NCBI
99.	Takuma Y and Nouso K: Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol. 16:1436–1441. 2010. View Article : Google Scholar : PubMed/NCBI
100.	Duan XY, Qiao L and Fan JG: Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 11:18–27. 2012. View Article : Google Scholar : PubMed/NCBI
101.	Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA and Tsung A: Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 55:1809–1819. 2012. View Article : Google Scholar : PubMed/NCBI
102.	Li T, Qin LX, Gong X, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L and Fan J: Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer. 119:126–135. 2013. View Article : Google Scholar
103.	Malik SM, Gupte PA, de Vera ME and Ahmad J: Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 7:800–806. 2009. View Article : Google Scholar : PubMed/NCBI
104.	Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M and Borzio F: Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 7:580–585. 2009. View Article : Google Scholar : PubMed/NCBI
105.	Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N and Shiratori K: Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 45:960–967. 2010. View Article : Google Scholar : PubMed/NCBI
106.	Kusakabe A, Tanaka Y, Orito E, Sugauchi F, Kurbanov F, Sakamoto T, Shinkai N, Hirashima N, Hasegawa I, Ohno T, Ueda R and Mizokami M: A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol. 42:298–305. 2007. View Article : Google Scholar : PubMed/NCBI
107.	Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A and Osaki Y: Clinical characteristics of nonBnonC-HCC: comparison with HBV and HCV related HCC. Intervirology. 50:24–31. 2007. View Article : Google Scholar : PubMed/NCBI
108.	Nishikawa H, Osaki Y, Takeda H, Sakamoto A, Saito S, Nishijima N, Nasu A, Arimoto A, Kita R and Kimura T: Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma. J Gastrointestin Liver Dis. 22:173–181. 2013.PubMed/NCBI
109.	Cauchy F, Zalinski S, Dokmak S, Fuks D, Farges O, Castera L, Paradis V and Belghiti J: Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg. 100:113–121. 2013. View Article : Google Scholar : PubMed/NCBI